# GLP-1 agonists

Rating: Proven — Replicated results in human randomized trials
Type: Compound
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/glp-1-peptides-semaglutide-tirzepatide-retatrutide.html

> GLP-1 receptor agonists are incretin-mimicking drugs with large randomized-trial evidence for weight loss: semaglutide about 15%, tirzepatide about 21%, and retatrutide up to about 30% in phase 3. Semaglutide also cut major cardiovascular events 20% in the 17,604-person SELECT trial. The caveats are lean-mass loss (25-39% of weight lost), rapid regain after stopping, and unproven claims such as slowed epigenetic aging, which rest on one small post-hoc analysis.

> The incretin revolution represents the most significant pharmacological advance in metabolic medicine since insulin. But the story is more complex than the hype suggests — and the long-term implications remain uncertain.

## Overview

Glucagon-like peptide-1 (GLP-1) receptor agonists and multi-receptor agonists represent a paradigm shift in treating obesity, type 2 diabetes, and cardiometabolic disease. Three agents dominate the current and emerging landscape:

Agent | Generation | Receptors Targeted | Brand Names | Status (2026)  
---|---|---|---|---  
**Semaglutide** | 1st (single) | GLP-1R | Ozempic (T2D), Wegovy (obesity), Rybelsus (oral) | Approved, widely available  
**Tirzepatide** | 2nd (dual) | GLP-1R + GIPR | Mounjaro (T2D), Zepbound (obesity) | Approved  
**Retatrutide** | 3rd (triple) | GLP-1R + GIPR + GCG-R | LY3437943 (investigational) | Phase 3 — pending approval  
  
### The Core Mechanism

GLP-1 is an **incretin hormone** — released from intestinal L-cells within minutes of eating. It: \- Stimulates glucose-dependent insulin secretion from pancreatic β-cells \- Suppresses glucagon release \- Slows gastric emptying \- Sends satiety signals to the brain (hypothalamus, brainstem) \- Reduces food reward signaling in the mesolimbic system

**The problem:** Endogenous GLP-1 has a half-life of ~2 minutes (rapidly degraded by DPP-4 enzyme). The drugs resist this degradation.

## Mechanisms of Action

### Semaglutide (GLP-1 Receptor Agonist)

  * **Modified GLP-1 analog** with amino acid substitutions at position 8 (Ala→Aib) and 34 (Lys→Arg)
  * **C-18 fatty di-acid chain** enables albumin binding → half-life ~1 week
  * **Receptor potency:** Similar to native GLP-1
  * **Primary effects:**
  * Potent appetite suppression via hypothalamic POMC neuron activation
  * Delayed gastric emptying (contributing to early satiety)
  * Enhanced insulin secretion (glucose-dependent — low hypoglycemia risk)
  * Glucagon suppression
  * Anti-inflammatory effects on vascular endothelium
  * Direct cardioprotective effects (independent of weight loss)



### Tirzepatide (GLP-1/GIP Dual Agonist)

  * **39 amino acid peptide** based on GIP backbone with GLP-1 receptor activity
  * **First-in-class dual agonist** — simultaneous GLP-1R and GIPR activation
  * **Receptor potency:** GLP-1R similar to native; GIPR slightly lower than native GIP
  * **Why dual is better:**
  * GIP receptor activation adds **complementary appetite suppression**
  * GIP inhibits hindbrain emesis neurons → **reduced nausea** vs. GLP-1 alone
  * GIP enhances adipose tissue lipid buffering → improved insulin sensitivity beyond weight loss alone
  * GIP may preserve lean mass better than GLP-1 monotherapy



### Retatrutide (GLP-1/GIP/Glucagon Triple Agonist)

  * **39 amino acid single peptide** from GIP backbone with C20 fatty di-acid moiety
  * Once-weekly SC injection (half-life ~6 days)
  * **Receptor potency vs. human hormones:**
  * GLP-1R: 2.5× lower potency than native GLP-1
  * GIPR: 8.9× higher potency than native GIP
  * GCG-R: 2.9× lower potency than native glucagon
  * **Why add glucagon receptor?**
  * Glucagon agonism increases **energy expenditure** (thermogenesis)
  * Reduces hepatic lipid accumulation
  * Bariatric surgery raises all three hormones simultaneously — triple agonism mimics this more closely
  * **Concern:** Glucagon promotes protein catabolism → potential **accelerated lean mass loss**



## Clinical Evidence

### Semaglutide

#### Weight Loss (STEP Program)

Trial | Population | Dose | Duration | Weight Loss  
---|---|---|---|---  
**STEP 1** | Obesity/BMI ≥30 | 2.4 mg weekly | 68 weeks | **−14.9%** vs −2.4% placebo  
**STEP 2** | T2D + overweight | 2.4 mg weekly | 68 weeks | **−9.6%** vs −3.4% placebo  
**STEP 4** | Continued vs withdrawal | 2.4 mg weekly | 68 weeks | **−17.4%** (continued) vs −5.0% (withdrawn)  
**STEP 5** | 2-year extension | 2.4 mg weekly | 104 weeks | **−15.2%** sustained  
  
_PMID[33442145](https://pubmed.ncbi.nlm.nih.gov/33442145/) (STEP 1), 33567403 (STEP 2), 35442970 (STEP 4)_

#### Cardiovascular Outcomes (SELECT Trial)

  * **N = 17,604** — overweight/obese + established CVD, no diabetes
  * **20% reduction in MACE** (CV death, nonfatal MI, stroke) vs placebo (HR 0.80, p<0.001)
  * Benefits **largely independent of weight loss** — direct cardioprotective effect
  * Waist circumference reduction independently associated with lower CV risk
  * _PMID[37952107](https://pubmed.ncbi.nlm.nih.gov/37952107/)_



#### Heart Failure (STEP-HFpEF)

  * Semaglutide improved heart failure symptoms and physical function in obesity-related HFpEF
  * Dual benefit: diuretic effect + weight-mediated cardiac unloading



### Tirzepatide

#### Weight Loss (SURMOUNT Program)

Trial | Population | Dose | Duration | Weight Loss  
---|---|---|---|---  
**SURMOUNT-1** | Obesity (no T2D) | 15 mg weekly | 72 weeks | **−20.9%** vs −3.1% placebo  
**SURMOUNT-2** | T2D + obesity | 15 mg weekly | 72 weeks | **−15.7%** vs −3.2% placebo  
**SURMOUNT-3** | Continued + lifestyle | 15 mg weekly | 84 weeks | **−26.6%** (total)  
**SURMOUNT-4** | Long-term extension | 15 mg weekly | 88 weeks | **−25.3%** sustained  
  
_PMID[37111956](https://pubmed.ncbi.nlm.nih.gov/37111956/) (SURMOUNT-1), 37952107 (SURMOUNT-2)_

#### Additional Benefits

  * **Obstructive sleep apnea:** Significant improvement (SURMOUNT-OSA)
  * **MASH (fatty liver disease):** Resolution in substantial proportion of patients
  * **Heart failure with preserved ejection fraction:** Benefit demonstrated (SURPASS program)



### Retatrutide

#### Phase 2 Obesity Trial (48 weeks, N=338)

Outcome | Placebo | Retatrutide 12 mg  
---|---|---  
**Body weight change** | −2.1% | **−24.2%**  
**≥20% WL achieved** | 1% | **64%**  
**≥30% WL achieved** | 0% | **26%**  
**Triglycerides** | +1.4% | **−39.9%**  
**LDL cholesterol** | −0.3% | **−21.7%**  
**Liver fat (substudy)** | +0.3% | **−82.4%**  
  
  * No evidence of weight loss plateau at 48 weeks
  * Greater weight loss in women (−28.5% vs −21.9% in men)
  * Phase 3 TRIUMPH program ongoing → **28.7% weight loss** reported in Phase 3 (2025)



_PMID[37952107](https://pubmed.ncbi.nlm.nih.gov/37952107/) (phase 2 data), Lilly press releases 2025 (TRIUMPH-4)_

## GLP-1 Drugs and Biological Aging — Landmark 2026 Evidence

### First RCT Evidence: Semaglutide Slows Epigenetic Aging

A landmark 2026 study (Corley MJ et al., _Nature Communications_ , May 2026) provides the **first randomized, placebo-controlled clinical evidence** that a GLP-1 receptor agonist slows biological aging in humans.

**Study details:** \- **Design:** Phase 2b, double-blind, placebo-controlled RCT — post hoc epigenetic analysis \- **Population:** N=84 adults with HIV-associated lipohypertrophy ([NCT04019197](https://clinicaltrials.gov/study/NCT04019197)) \- **Intervention:** Weekly semaglutide vs placebo for 32 weeks \- **Assay:** DNA methylation-based epigenetic clocks from peripheral blood mononuclear cells (baseline vs Week 32) \- **PMID:** [42156721](https://pubmed.ncbi.nlm.nih.gov/42156721/) · [PMC13381876](https://pmc.ncbi.nlm.nih.gov/articles/PMC13381876/) | DOI: [10.1038/s41467-026-72861-3](https://doi.org/10.1038/s41467-026-72861-3)

**Key results (semaglutide vs placebo):**

Epigenetic Clock | Result | P-value | Significance  
---|---|---|---  
**DunedinPACE** (pace of aging) | −9% slower biological aging | 0.01 | ↓ Rate of aging  
**PhenoAge** | −4.9 years biological age reduction | 0.004 | Broad systemic aging  
**PCGrimAge** | −3.1 years (mortality risk-linked) | 0.007 | ↓ All-cause mortality risk markers  
**GrimAge V2** | −2.3 years | 0.009 | ↓ Age-related disease risk markers  
**OMICmAge** | −2.2 years | 0.009 | Multi-omic systems readout (4th-gen)  
**RetroAge** | −2.2 years | 0.030 | Retroelement-based epigenetic clock  
  
**System-specific findings:** The epigenetic improvements spanned aging measures associated with **blood, brain, heart, liver, kidneys, and metabolic health** — suggesting broad systemic effects rather than tissue-specific action.

### Complementary Pilot Study (npj Aging, 2026)

A second pilot study (Corley et al., _npj Aging_ , 2026) examined semaglutide in HIV+ adults with MASLD (fatty liver disease) over 24 weeks:

  * **42% of participants** showed reduced pace of biological aging (DunedinPACE) — and those responders also had greater liver fat reduction
  * **34%** showed slowed mortality-risk aging markers (PCGrimAge)
  * **~49%** showed increased telomere length markers (PCDNAmTL) — and those responders showed improved physical function (faster walking speed)



DOI: [10.1038/s41514-026-00383-9](https://doi.org/10.1038/s41514-026-00383-9)

### Proposed Mechanisms for Aging Effects

  1. **Reduced chronic immune activation** — GLP-1 drugs lower systemic inflammation, a primary driver of accelerated aging
  2. **Visceral/ectopic fat reduction** — Fat tissue secretes inflammatory and metabolic signals (adipokines, cytokines) that promote aging; reducing this burden quiets those signals
  3. **Cellular reprogramming** — Emerging data suggest GLP-1 drugs may reprogram certain cells across organs, explaining the multi-system epigenetic clock improvements (per Corley)
  4. **Reduced cellular senescence burden** — Lower inflammatory load may reduce SASP-driven paracrine senescence → see [Senolytics](senolytics.html)



### Critical Caveats

  * **HIV-specific population:** People with HIV experience accelerated aging due to chronic inflammation and antiretroviral therapy. Results may not fully generalize, though the underlying aging biology is shared.
  * **Surrogate endpoints:** Epigenetic clocks are biomarkers, not direct clinical outcomes (lifespan, disease incidence). Slowing a clock ≠ extending life.
  * **Short duration:** 32 weeks is insufficient to establish durability or long-term effects.
  * **Post hoc analysis:** This was a secondary analysis of data from a trial originally designed to study lipohypertrophy, not aging.
  * **Author COI:** Corley serves as scientific advisor for TruDiagnostic (a commercial epigenetic testing company).



> "We are not saying that semaglutide reverses aging or makes people younger. What we are seeing is a signal that it may slow some of the biological processes associated with aging." — Michael Corley, PhD

### Research Implications

The Stein Institute for Research on Aging (UCSD) plans to translate these findings into individualized **"aging dashboards"** using epigenetic clocks to track biological aging and design personalized therapies. Future trials will need to test: \- Whether effects replicate in non-HIV populations \- Whether tirzepatide and retatrutide have distinct or enhanced aging effects \- Optimal dosing and treatment duration \- Whether combining GLP-1 therapy with lifestyle interventions (exercise, [dietary restriction](fasting-approaches.html), sleep optimization) enhances aging benefits

## Critical Analysis

### What the Pharma Industry Doesn't Emphasize

#### 1\. Lean Mass Loss — The Sarcopenia Risk ⚠️

**Up to 39% of weight lost on GLP-1 therapy may come from lean mass** (muscle, bone, organ tissue), not just fat. This is _not_ proportional to total weight loss — it's accelerated.

  * Systematic review (PMID [38629387](https://pubmed.ncbi.nlm.nih.gov/38629387/)): "Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass."
  * Muscle loss is _not_ benign — sarcopenia is independently associated with mortality, falls, frailty, and metabolic decline
  * **The "Ozempic face"** phenomenon reflects more than cosmetic change — it signals global protein catabolism



#### 2\. Long-Term Dependency

  * STEP 4 showed that **withdrawal leads to rapid regain** (two-thirds of lost weight within 1 year)
  * This suggests these drugs may need to be taken **indefinitely** — a $1,000+/month commitment
  * The business model is clear: chronic medication for chronic condition
  * Weight regain after discontinuation may leave patients **worse off metabolically** than baseline due to lost lean mass



#### 3\. Unknown Long-Term Effects

  * GLP-1 receptors are expressed throughout the body: pancreas, brain, heart, kidneys, GI tract, thyroid C-cells
  * **Thyroid C-cell hyperplasia and tumors** observed in rodent studies (not confirmed in humans, but monitored)
  * Pancreatitis risk (rare but serious)
  * **Gastroparesis** — chronic delayed gastric emptying that may persist after discontinuation
  * Effects on gut microbiome are poorly characterized
  * Impact on mood, depression, and suicidal ideation under FDA investigation (EU investigation initiated 2024)



#### 4\. The Reductionist Trap

These drugs address a **symptom** (excess body weight) without addressing **root causes** : \- Ultra-processed food environment \- Insulin resistance from chronic carbohydrate excess \- Sedentary lifestyle \- Sleep deprivation and circadian disruption \- Chronic stress and cortisol dysregulation \- Environmental obesogens (endocrine disruptors)

See also: [Metabolic Health and Insulin](metabolic-health-and-insulin.html) → [Fasting Protocols](fasting-approaches.html) → [Ketogenic Approaches](ketogenic-approaches.html)

## Doses in studies

### Retatrutide (investigational)

  * Phase 3 trials escalated from 2 mg to 12 mg weekly
  * Not yet approved — clinical trials only



## Natural GLP-1 Enhancement

Before or alongside pharmaceutical GLP-1 therapy, evidence supports natural approaches:

Intervention | Mechanism | Evidence  
---|---|---  
**Soluble fiber** (psyllium, inulin, acacia) | Fermented to SCFAs → stimulates L-cell GLP-1 secretion | ★★ Moderate  
**Berberine** (500mg TID) | DPP-4 inhibition + AMPK activation + GLP-1 upregulation | ★★ Moderate  
**Bitter melon** | GLP-1 receptor activation + DPP-4 inhibition | ★ Emerging  
**Green tea catechins** | DPP-4 inhibition, antioxidant protection of L-cells | ★ Emerging  
**Curcumin** | Anti-inflammatory → improved L-cell function | ★ Emerging  
**High-protein meals** | Direct stimulation of GLP-1 and PYY release | ★★ Moderate  
**Exercise** (especially HIIT) | Acute GLP-1 and GLP-1 sensitization | ★★ Moderate  
**Ginsenosides** (Panax ginseng) | GLP-1 secretion enhancement | ★ Emerging  
**Resistant starch** | SCFA production → L-cell stimulation | ★★ Moderate  
  
> **Key insight:** Natural approaches cannot match the pharmacological potency of GLP-1 agonists. However, they may reduce the required dose, support lean mass preservation, and address root metabolic dysfunction. The optimal approach combines pharmacotherapy with metabolic optimization.

## Contraindications & Drug Interactions

### Absolute Contraindications

  * Personal or family history of **medullary thyroid carcinoma** (MTC)
  * **Multiple Endocrine Neoplasia syndrome type 2** (MEN2)
  * History of **pancreatitis**
  * **Severe gastroparesis**



### Relative Contraindications / Caution

  * History of **depression or suicidal ideation** (FDA monitoring)
  * **Eating disorders** (may mask or worsen)
  * **Pregnancy** ( Category X — animal toxicity; stop 2 months before conception)
  * **Gallbladder disease** (increased risk of cholelithiasis with rapid weight loss)
  * **Renal impairment** (monitor eGFR — mostly reassuring data)
  * Concurrent **insulin or sulfonylureas** (hypoglycemia risk — dose adjust)



## Research Gaps & Future Directions

  1. **Lean mass preservation** — Ongoing trials combining GLP-1 with anti-myostatin antibodies or anabolic agents
  2. **Oral GLP-1 agonists** — Orforglipron (Lilly, Phase 3) and danuglipron (Pfizer) in development
  3. **Quadruple agonists** — Preclinical work adding amylin or PYY receptor activity
  4. **Combination with senolytics** → [Senolytics](senolytics.html) — clearing senescent cells during weight loss
  5. **Microbiome interactions** — GLP-1 drugs alter gut motility and flora composition; long-term effects unknown
  6. **Cancer risk** — Long-term surveillance for thyroid, pancreatic, and colorectal effects
  7. **Biological aging** — The Corley et al. 2026 RCT (PMID [40791720](https://pubmed.ncbi.nlm.nih.gov/40791720/)) provides the first human evidence that semaglutide slows epigenetic aging across multiple clocks. This opens an entirely new research frontier: whether GLP-1 drugs are geroscience interventions, not just metabolic drugs. See dedicated section above.



## Retatrutide and Next-Generation GLP-1 Multi-Agonists — Clinical Translation

### Overview

Retatrutide (LY3437943) is Eli Lilly's investigational once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors. As of August 2026, five Phase 3 trials have reported results across the TRIUMPH program. It is the most advanced triple hormone receptor agonist in clinical development, demonstrating weight loss of up to **−30.3% at 104 weeks** (TRIUMPH-1, 12 mg) — exceeding all approved anti-obesity medications.

**Key differentiator:** The glucagon receptor agonism component drives hepatic fat oxidation, thermogenesis, and increased energy expenditure through mechanisms not accessible to GLP-1-only or GLP-1/GIP dual agonists. This addresses both sides of the energy balance equation (appetite suppression + energy expenditure).

### Mechanism of Action — Triple Receptor Agonism

Receptor | Primary Effects | Clinical Translation  
---|---|---  
**GLP-1R** | Central appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion | Reduced caloric intake, glycemic control  
**GIPR** | Enhanced insulin secretion, modulation of lipid storage, improved adipose tissue quality | Synergistic weight loss with GLP-1; reduced GI side effects vs GLP-1 alone  
**GCGR (Glucagon)** | Hepatic fatty acid β-oxidation, thermogenesis, lipolysis, increased energy expenditure | Targets visceral/liver fat; potential lean mass preservation via energy expenditure  
  
**Glucagon receptor specifically:** \- Upregulates hepatic fatty acid β-oxidation (direct liver fat reduction) \- Promotes lipolysis in adipose tissue via G-protein coupled receptor action \- Activates brown adipose tissue (BAT) thermogenesis and UCP1-independent futile calcium cycling (SERCA2b-mediated) \- Plin5 induction improves coupling between lipid droplet lipolysis and mitochondrial oxidation \- Net effect: increased resting energy expenditure beyond what appetite suppression alone achieves

> **Source:** Multi-omic profiling, _Diabetol Metab Syndr_ 2026;18:article 2116. doi [10.1186/s13098-026-02116-0](https://doi.org/10.1186/s13098-026-02116-0).

* * *

### Trial Summary

Trial | Phase | Indication | N | Duration | Status | Key Result (12 mg)  
---|---|---|---|---|---|---  
TRIUMPH-1 | 3 | Obesity | 2,339 | 80-104 wks | **Complete** | **−28.3%** (80w) / **−30.3%** (104w)  
TRIUMPH-2 | 3 | Obesity + T2D | 1,152 | 80 wks | **Topline** | **−20.8%** weight; A1C −1.5%  
TRIUMPH-3 | 3 | Obesity + CVD | 1,949 | 80 wks | **Topline** | **−22.6%** weight  
TRIUMPH-4 | 3 | Obesity + Knee OA | 445 | 68 wks | **Complete** | **−28.7%** weight; 74-76% pain reduction  
TRANSCEND-T2D-1 | 3 | Type 2 Diabetes | — | 40 wks | **Complete** | **−16.8%** weight; A1C −2.0%  
TRIUMPH-5 | 3 | Obesity (vs tirzepatide) | ~800 | — | **Active** | Head-to-head body weight primary  
TRIUMPH-6 | 3b | Weight Maintenance | 643 | — | **Active** | —  
TRIUMPH-Outcomes | 3 | CV/Renal Outcomes | ~10,000 | Multi-year | **Active** | CV composite + kidney endpoints  
TRIUMPH-7 | 3 | Obesity + Low Back Pain | 586 | — | **Recruiting** | —  
  
### TRIUMPH-1 — Pivotal Obesity Trial (May 2026)

Detail | Value  
---|---  
NCT | [NCT05929066](https://clinicaltrials.gov/study/NCT05929066)  
Design | Phase 3, double-blind, placebo-controlled master trial with nested OSA and OA protocols  
Participants | 2,339 randomized (532 in 104-week extension)  
Baseline | Mean ~112.7 kg, BMI 40.0  
Doses | —  
Duration | 80 weeks (extension to 104 weeks for BMI ≥35 subgroup)  
  
**Weight loss at 80 weeks:**

**Weight loss at 104 weeks (BMI ≥35 extension):**

**Categorical weight loss at 12 mg:** \- ≥5% body weight: 100% \- ≥10%: ~98% \- ≥15%: ~93% \- ≥20%: ~75% \- ≥25%: 62.5% \- ≥30%: 45.3% \- ≥35%: 27.2%

**Body composition transformation:** \- 65.3% of participants reached BMI <30 (non-obese category) \- 37.5% of class 3 obesity subgroup achieved normal BMI \- Waist circumference: −24.1 cm mean reduction \- Significant improvements in lipids, blood pressure, hsCRP

**Nested basket trials within TRIUMPH-1:** \- **Knee osteoarthritis (n=574):** Significant pain reduction and functional improvement \- **Obstructive sleep apnea (n=243):** Marked improvement in apnea-hypopnea index

> **Sources:** Eli Lilly investor release, May 21, 2026. AJMC, May 2026. ADA 2026 Scientific Sessions presentations.

* * *

### TRIUMPH-2 — Obesity with Type 2 Diabetes (July 2026)

Detail | Value  
---|---  
NCT | [NCT05929079](https://clinicaltrials.gov/study/NCT05929079)  
Participants | 1,152 (1:1:1:1 to 4/9/12 mg or placebo)  
  
**Results at 12 mg:** \- Weight loss: **−20.8%** \- HbA1c reduction: **−1.5%** (9 mg: −1.6%) \- Discontinuation due to AE: 3.8% (4 mg), 11.6% (9 mg), 7.7% (12 mg) vs 4.8% placebo

> **Source:** Eli Lilly press release, July 23, 2026.

* * *

### TRIUMPH-3 — Obesity with Cardiovascular Disease (July 2026)

Detail | Value  
---|---  
Participants | 1,949  
Duration | 80 weeks  
  
**Results at 12 mg:** \- Weight loss: **−22.6%** in a population with established cardiovascular disease \- Discontinuation due to AE: 9.8% (9 mg), 13.5% (12 mg) vs 4.8% placebo (higher rates in sicker population) \- AE profile: GI-dominant; diarrhea (30.1%/24.4% at 9/12 mg vs 8.7% placebo), nausea (21.7%/22.4% vs 5.8%) \- **Dysesthesia** (skin tingling/abnormal sensation): 6.4%/6.4% at 9/12 mg vs 1.3% placebo — a signal unique to retatrutide, possibly related to glucagon receptor activity

> **Source:** Eli Lilly press release, July 23, 2026. TRIUMPH-3 topline.

* * *

### TRIUMPH-4 — Knee Osteoarthritis (December 2025)

Detail | Value  
---|---  
NCT | [NCT05931367](https://clinicaltrials.gov/study/NCT05931367)  
Participants | 445  
Duration | 68 weeks  
  
**Results at 12 mg:** \- Weight loss: **−28.7%** \- WOMAC pain reduction: 74-76% \- Significant physical function gains

> **Source:** Results reported December 2025.

* * *

### TRANSCEND-T2D-1 — Type 2 Diabetes (March 2026)

Detail | Value  
---|---  
Duration | 40 weeks  
  
**Results at 12 mg:** \- Weight loss: **−16.8%** \- HbA1c reduction: **−1.7% to −2.0%** \- Published simultaneously in _The Lancet_ and presented at ADA 2026

> **Source:** _The Lancet_ , March 2026. ADA 2026 Scientific Sessions.

* * *

### Phase 2 Obesity — NEJM 2023 (Jastreboff et al.)

48-week trial, 338 participants. **−24.2% at 12 mg** (−22.8% at 8 mg). This was the trial that established retatrutide as the most potent weight-loss agent in clinical development.

> Jastreboff AM et al. _N Engl J Med_ 2023;389:514-526. doi [10.1056/NEJMoa2301972](https://doi.org/10.1056/NEJMoa2301972).

### Phase 2 T2D — Lancet 2023 (Rosenstock et al.)

36-week trial, 281 participants. HbA1c **−2.02%** at 12 mg; 67% achieved normoglycemia (HbA1c <5.7%). Weight loss **−16.94%** at 12 mg.

> Rosenstock J et al. _The Lancet_ 2023\. PMID [37385280](https://pubmed.ncbi.nlm.nih.gov/37385280/).

### Phase 2 Liver Fat Substudy — Nature Medicine 2024

  * **81-86% relative liver fat reduction** at higher doses (MRI-PDFF)
  * 78-90% achieved ≥30% liver fat reduction
  * 52-69% achieved liver fat normalization (<5%)
  * Among the strongest liver fat reductions reported for any pharmacotherapy



> _Nature Medicine_ 2024\. doi [10.1038/s41591-024-03018-2](https://doi.org/10.1038/s41591-024-03018-2).

* * *

### Gastrointestinal Events (Most Common)

AE | 4 mg | 9 mg | 12 mg | Placebo  
---|---|---|---|---  
Nausea | 28.6% | 38.4% | 42.4% | 14.8%  
Diarrhea | 25.2% | 34.1% | 32.0% | 13.5%  
  
  * Mostly mild-to-moderate, clustered during dose escalation
  * Starting at 2 mg (not 4 mg) partially mitigates GI severity



### Discontinuation Due to AEs (TRIUMPH-1)

Arm | Discontinuation  
---|---  
Placebo | 4.9%  
4 mg | 4.1%  
9 mg | 6.9%  
12 mg | 11.3%  
  
### Cardiac Safety Concerns

  * **Heart rate increase:** Dose-dependent, up to +6.7 bpm at 24 weeks, declining thereafter
  * **Cardiac arrhythmias:** Mild to moderate (exception: one case of acute pancreatitis in Phase 2)
  * No increased MACE (major adverse cardiovascular events) observed in Phase 2
  * **TRIUMPH-Outcomes trial (~10,000 participants)** is specifically designed to evaluate long-term CV safety at scale
  * Heart rate increases counteract some benefits of weight loss; requires monitoring



### Unique Signal: Dysesthesia

  * Skin tingling/abnormal sensation reported in TRIUMPH-3 (6.4% at 9/12 mg vs 1.3% placebo)
  * Possibly related to glucagon receptor activity (not seen with GLP-1/GIP dual agonists)
  * Clinical significance unclear; under investigation



* * *

### Body Composition and Muscle Preservation

Retatrutide shows favorable lean mass retention relative to total weight loss in available substudies. The glucagon receptor agonism is hypothesized to support energy expenditure and mitigate sarcopenia through:

  * Increased thermogenesis and resting energy expenditure
  * Enhanced hepatic fatty acid β-oxidation (spares muscle protein catabolism)
  * Adipose tissue metabolic reprogramming toward catabolic state (Plin5 induction, reduced acyl-carnitines)
  * Improved coupling between lipid droplet lipolysis and mitochondrial oxidation



**Human data highlights:** \- Lean mass loss proportion appears comparable to semaglutide/tirzepatide despite greater absolute weight loss \- Body composition substudies from Phase 2/3 are ongoing

> **Sources:** Coskun T et al. _Lancet Diabetes Endocrinol_ 2025 (body composition substudy). Berkovic MC et al. [PMC12444289](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444289/) (muscle preservation review 2025).

* * *

### Regulatory Pathway and Timeline

  * **BLA filing:** Q1 2027 (planned)
  * **TRIUMPH-1, -2, -3:** All reported (pivotal registrational data)
  * **Approval window:** Late 2027 – 2028
  * **TRIUMPH-5 (head-to-head vs tirzepatide):** Ongoing; will determine comparative positioning
  * **TRIUMPH-Outcomes:** Multi-year; required for CV safety label claims



* * *

### Competitive Landscape

Agent | Company | Class | Max Weight Loss | Status  
---|---|---|---|---  
**Retatrutide** | Lilly | Triple (GLP-1/GIP/GCG) | −30.3% | Phase 3 complete  
Tirzepatide | Lilly | Dual (GLP-1/GIP) | −22.5% | Approved (Zepbound)  
Semaglutide | Novo Nordisk | GLP-1 | −14.9% | Approved (Wegovy)  
Orforglipron | Lilly | GLP-1 (small molecule) | −11.2% (ATTAIN-1, 36 mg) | **Approved Apr 2026 (Foundayo)**  
CagriSema | Novo Nordisk | GLP-1 + amylin | −23.9% (REDEFINE-1 DXA sub) | NDA filed Dec 2025; decision late 2026  
Mazdutide | Innovent | GLP-1/GCG | Phase 3 | Phase 3 (China)  
Amycretin | Novo Nordisk | GLP-1/amylin | Phase 2 | Phase 2  
  
* * *

### Commercial and Clinic Angles

  * **Market disruption:** If approved, retatrutide would be the most effective anti-obesity medication by a wide margin
  * **Clinic economics:** Potential to shift GLP-1 clinic models toward triple agonist protocols
  * **Muscle preservation protocols:** Pairing with resistance training, BPC-157/TB-500, and GlyNAC
  * **Personalization:** Metabolic-longevity clinics positioning retatrutide as a precision obesity intervention
  * **MASLD/MASH:** 81-86% liver fat reduction could capture the massive MASLD market (25% of global adults)



* * *

### Evidence Separation Summary

Domain | Human Evidence | Preclinical  
---|---|---  
Weight loss | Phase 3 (TRIUMPH-1/2/3/4): −20.8% to −30.3% | Strong (multi-species)  
Glycemic control (T2D) | Phase 3 (TRANSCEND-T2D-1): A1C −2.0% | Strong  
Liver fat (MASLD) | Phase 2: 81-86% reduction | Strong  
Muscle preservation | Substudies (ongoing) | Favorable signals  
CV outcomes | Ongoing (TRIUMPH-Outcomes, ~10k) | Mixed (heart rate concern)  
Knee OA pain | Phase 3 (TRIUMPH-4): 74-76% reduction | —  
  
* * *

### Wikilinks

  * 01 - Peptides/GLP-1 Peptides (Semaglutide, Tirzepatide, Retatrutide)
  * 01 - Peptides/GLP-1 Muscle Preservation - Evidence and Protocol Intelligence
  * 11 - Longevity and Anti-Aging/Metformin and Rapamycin
  * 08 - Nutrition and Eating/Metabolic Health and Insulin
  * 09 - Human Biology Optimization/Mitochondrial Health
  * 09 - Human Biology Optimization/Urolithin A - Mitophagy Inducer
  * 01 - Peptides/GlyNAC and Glutathione Precursors - Evidence Taxonomy
  * 01 - Peptides/BPC-157 (Body Protection Compound)
  * 01 - Peptides/TB-500 (Thymosin Beta-4)



* * *

## Sources

1. PubMed 33442145 (PubMed 33442145)
2. PubMed 37952107 (PubMed 37952107)
3. PubMed 37111956 (PubMed 37111956)
4. NCT04019197 (NCT04019197)
5. PubMed 42156721 (PubMed 42156721)
6. PMC13381876 (PMC13381876)
7. DOI 10.1038/s41467-026-72861-3 (DOI 10.1038/s41467-026-72861-3)
8. DOI 10.1038/s41514-026-00383-9 (DOI 10.1038/s41514-026-00383-9)
9. PubMed 38629387 (PubMed 38629387)
10. PubMed 40791720 (PubMed 40791720)
11. PMC11848261 (PMC11848261)
12. PubMed 35442970 (PubMed 35442970)
13. PubMed 39216535 (PubMed 39216535)
14. DOI 10.1186/s13098-026-02116-0 (DOI 10.1186/s13098-026-02116-0)
15. NCT05929066 (NCT05929066)
16. NCT05929079 (NCT05929079)
17. NCT05931367 (NCT05931367)
18. DOI 10.1056/NEJMoa2301972 (DOI 10.1056/NEJMoa2301972)
19. PubMed 37385280 (PubMed 37385280)
20. DOI 10.1038/s41591-024-03018-2 (DOI 10.1038/s41591-024-03018-2)
21. PMC12444289 (PMC12444289)